Ionis Pharmaceuticals
IONS
363 hedge funds and large institutions have $7.27B invested in Ionis Pharmaceuticals in 2023 Q4 according to their latest regulatory filings, with 85 funds opening new positions, 108 increasing their positions, 116 reducing their positions, and 28 closing their positions.
204% more first-time investments, than exits
New positions opened: 85 | Existing positions closed: 28
17% more funds holding
Funds holding: 310 → 363 (+53)
15% more capital invested
Capital invested by funds: $6.35B → $7.27B (+$922M)
2.63% more ownership
Funds ownership: 97.49% → 100.12% (+2.6%)
5% more call options, than puts
Call options by funds: $34.6M | Put options by funds: $32.9M
0% more funds holding in top 10
Funds holding in top 10: 6 → 6 (0)
7% less repeat investments, than reductions
Existing positions increased: 108 | Existing positions reduced: 116
Top Buyers
Top Sellers
IONS Hedge Fund Activity: Q4 2023 in Review
363 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Ionis Pharmaceuticals (IONS) for Q4 2023, worth a combined $7.27B — up 15% from $6.35B a quarter earlier.
Buyers outnumbered sellers: 85 funds opened new IONS positions and 28 closed out — a net gain of 57 holders — while 108 added to existing stakes and 116 trimmed.
The largest buyer was Wellington Management Group, adding an estimated $137M. The largest seller was Deep Track Capital, cutting an estimated $75.9M.
- 363 institutional investors held Ionis Pharmaceuticals (IONS) as of Q4 2023, up from 310 in Q3 2023.
- Funds reported $7.27B of Ionis Pharmaceuticals stock for Q4 2023, up 15% quarter-over-quarter.
- 85 funds opened new Ionis Pharmaceuticals positions in Q4 2023 and 28 closed out, a net change of +57 holders.
- The largest Ionis Pharmaceuticals buyer in Q4 2023 was Wellington Management Group, an estimated $137M added.
- The largest Ionis Pharmaceuticals seller in Q4 2023 was Deep Track Capital, an estimated $75.9M sold.
Based on aggregated 13F filings for Q4 2023.